Literature DB >> 11458053

Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy.

S C Dutta1, J A Smith, S B Shappell, C S Coffey, S S Chang, M S Cookson.   

Abstract

PURPOSE: The role of radical cystectomy in patients with nonmuscle invasive urothelial carcinoma of the bladder remains controversial. The risk of overtreatment must be balanced against the potential benefit of aggressive therapy. We reviewed our results in these patients with a particular emphasis on clinical under staging.
MATERIALS AND METHODS: We reviewed the records of 214 consecutive patients who underwent radical cystectomy for urothelial carcinoma between April 1995 and August 1999, focusing on those with nonmuscle invasive, stages T1 or less disease. We assessed clinical and pathological data as well as outcomes based on pathological disease extent.
RESULTS: A total of 78 patients (36%) underwent radical cystectomy for clinical stages T1 or less disease. Indications included disease refractory to intravesical therapy in 29 cases (37%), pathological findings reflective of high grade stage T1 or multifocal disease in 26 (33%), radiographic suspicion of invasive disease in 15 (20%) and severe symptoms in 8 (10%). Cancer was clinically under staged with stages pT2 or greater disease in 31 patients (40%) according to final pathology results. Under staging was most pronounced in the 10 patients (67%) with suspicious radiography and in the 18 (64%) with absent muscle in the biopsy specimen. Of the 78 patients with pathological stages pT1 disease or less 98% had no evidence of disease compared to 65% with stages pT2 or greater disease (p <0.01).
CONCLUSIONS: Despite the intent to perform early cystectomy a significant percent of patients harbored occult muscle invasive and/or metastatic disease. In clinical and pathological, superficial stages T1 or less cases disease-free survival was excellent. Due to these results, the selection of high risk superficial transitional cell carcinoma cases for continued bladder sparing treatment should include uninvolved muscle on biopsy and absent radiographic suspicion of invasion.

Entities:  

Mesh:

Year:  2001        PMID: 11458053

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  46 in total

1.  The value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications.

Authors:  S V Petrov; K A Malkhasyan; M Yu Ulyanin; E F Abdrakhmanov; R Sh Khasanov
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

Review 2.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  [Oncological diseases and postoperative alterations of the bladder and urinary tract].

Authors:  M M Ong; P Riffel; J Budjan; C Bolenz; S O Schönberg; S Haneder
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

Review 4.  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.

Authors:  Miguel Ramírez-Backhaus; José Domínguez-Escrig; Argimiro Collado; José Rubio-Briones; Eduardo Solsona
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

5.  Transurethral En Bloc Resection of Bladder Tumor Using an Endoscopic Submucosal Dissection Technique: Preliminary Results in an Animal Model.

Authors:  Shuichi Morizane; Takehiro Sejima; Hideto Iwamoto; Toshihiko Masago; Masashi Honda; Yuichiro Ikebuchi; Kazuya Matsumoto; Masaru Ueki; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

6.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

Review 7.  Use of nomograms as predictive tools in bladder cancer.

Authors:  Ahmad Shabsigh; Bernard H Bochner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

8.  Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Authors:  H Barton Grossman; Michael A O'Donnell; Michael S Cookson; Richard E Greenberg; Thomas E Keane
Journal:  Rev Urol       Date:  2008

Review 9.  Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Curr Urol Rep       Date:  2018-10-24       Impact factor: 3.092

10.  Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC).

Authors:  Tetsuya Shindo; Naoya Masumori; Hiroshi Kitamura; Toshiaki Tanaka; Fumimasa Fukuta; Tadashi Hasegawa; Masahiro Yanase; Masafumi Miyake; Noriomi Miyao; Atsushi Takahashi; Masanori Matsukawa; Keisuke Taguchi; Masanori Shigyo; Yasuharu Kunishima; Hitoshi Tachiki; Taiji Tsukamoto
Journal:  World J Urol       Date:  2013-11-05       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.